bis·phos·pho·nate

(bĭs′fŏs′fə-nāt′)

Any of a class of drugs that decrease bone resorption by inhibiting osteoclasts, used in the treatment of osteoporosis, Paget's disease, bone metastases, and other conditions. Also called diphosphonate.

[bis- + phosphon(ic acid), phosphorous acid (from phosphonium) + -ate.]

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

bisphosphonate

(ˌbɪsˈfɒsfəneɪt)

(Pharmacology) any drug of a class that inhibits the resorption of bone; used in treating certain bone disorders, esp osteoporosis

Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

Translations

bisphosphonate

n bisfosfonato

Mentioned in

References in periodicals archive

AMSTERDAM--Older women on bisphosphonate treatment for at least 3 years who then stopped taking the drug showed a 40% increased risk for hip fracture after they were off the bisphosphonate for more than 2 years, compared with women who never stopped using the drug, according to an analysis of more than 150,000 women in a Medicare database.

Bisphosphonate 'holidays' exceeding 2 years linked to increased fractures

Pamidronate-a bisphosphonate, was given I/V on monthly basis along with oral calcium.

THE EFFECT OF PAMIDRONATE ON BONE MINERAL DENSITY IN PRIMARY OSTEOPOROSIS IN PAKISTANI POPULATION

Bisphosphonate drugs, such as alendronate (Fosamax), ibandronate (Boniva) and zoledronic acid (Reclast), are proven to combat bone loss and fractures in people with the bone-thinning disease osteoporosis.

Osteoporosis drugs linked to a rare form of fracture: prolonged use of bisphosphonates raises the risk of side effects

Just under one-quarter of the women were on bisphosphonate therapy.

New data: Bisphosphonates may delay osteoarthritis

Several large, population-based, case-control studies have found a temporal relationship between bisphosphonate therapy and a statistically significant increased risk of subtrochanteric fractures.

Severe right hip pain: while this patient had osteoporosis, she hadn't experienced any recent trauma or falls that would explain her pain

Long-term bisphosphonate use has been suggested to result in suppressed bone remodelling and an increased risk of atypical fractures [1].

Treatment of Atypical Ulnar Fractures Associated with Long-Term Bisphosphonate Therapy for Osteoporosis: Autogenous Bone Graft with Internal Fixation

Bisphosphonate drugs are medications designed to treat osteoporosis by increasing bone density.

Guidelines for osteoporosis medications call for a 'drug holiday': for women who do not have a high fracture risk, a break from bisphosphonate drugs is advised

Bisphosphonates are specific inhibitors of osteoclastic activity and they reduce pathological fractures, skeletal related events and pain, and improve the quality of life in patients with metastatic cancers and multiple myeloma.1,2 Although usage of bisphosphonates is thought to be safe, in 2003, Marx and Stern reported the Bisphosphonate related osteonecrosis of the jaws (BRONJ).3 Nomenclature of this phenomenon changed as medication related osteonecrosis of the jaws (MRONJ ) in 2014.

Oncologists awareness about bisphosphonate related osteonecrosis of the jaws

The vast majority of atypical femur fractures are seen after long-term bisphosphonate use, and many doctors now recommend a five-year limit for taking them, with a periodic assessment of whether the drug is still necessary.

Atypical fracture

All randomized or prospective matched controlled trials that assessed the efficacy of bisphosphonate for elderly patients with hip fracture were included.

Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis